BrainStorm Cell Therapeutics Partners with Minaris to Advance Phase 3b ALS Clinical Trial for NurOwn®

Reuters05-27

BrainStorm Cell <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Partners with Minaris to Advance Phase 3b ALS Clinical Trial for NurOwn®

BrainStorm Cell Therapeutics Inc. $(BCLI)$ has announced a strategic partnership with Minaris Advanced Therapies for the manufacturing of its experimental therapy, NurOwn®, in preparation for a Phase 3b clinical trial aimed at treating amyotrophic lateral sclerosis (ALS). The collaboration involves a Letter of Intent for technology transfer and clinical trial manufacturing at Minaris' facility in Allendale, New Jersey. This partnership aims to enhance BrainStorm's manufacturing capabilities in the U.S. and is part of a broader strategy to support the upcoming clinical trial. Additionally, BrainStorm's collaboration with Pluri Inc. in Israel will contribute to the production of clinical trial materials. BrainStorm emphasizes its commitment to advancing the clinical development of NurOwn® through these strategic relationships.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainstorm Cell Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN96421) on May 27, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2538468472?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-27 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538468472","market":"nz","top_or_hot":-1,"title":"BrainStorm Cell Therapeutics Partners with Minaris to Advance Phase 3b ALS Clinical Trial for NurOwn®","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BrainStorm Cell <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Partners with Minaris to Advance Phase 3b ALS Clinical Trial for NurOwn®\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BrainStorm Cell Therapeutics Inc. <a href=\"https://laohu8.com/S/BCLI\">$(BCLI)$</a> has announced a strategic partnership with Minaris Advanced Therapies for the manufacturing of its experimental therapy, NurOwn®, in preparation for a Phase 3b clinical trial aimed at treating amyotrophic lateral sclerosis (ALS). The collaboration involves a Letter of Intent for technology transfer and clinical trial manufacturing at Minaris' facility in Allendale, New Jersey. This partnership aims to enhance BrainStorm's manufacturing capabilities in the U.S. and is part of a broader strategy to support the upcoming clinical trial. Additionally, BrainStorm's collaboration with <a href=\"https://laohu8.com/S/PLUR\">Pluri Inc.</a> in Israel will contribute to the production of clinical trial materials. BrainStorm emphasizes its commitment to advancing the clinical development of NurOwn® through these strategic relationships.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainstorm Cell Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN96421) on May 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BrainStorm Cell Therapeutics Partners with Minaris to Advance Phase 3b ALS Clinical Trial for NurOwn®</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBrainStorm Cell Therapeutics Partners with Minaris to Advance Phase 3b ALS Clinical Trial for NurOwn®\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-27 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BrainStorm Cell <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Partners with Minaris to Advance Phase 3b ALS Clinical Trial for NurOwn®\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BrainStorm Cell Therapeutics Inc. <a href=\"https://laohu8.com/S/BCLI\">$(BCLI)$</a> has announced a strategic partnership with Minaris Advanced Therapies for the manufacturing of its experimental therapy, NurOwn®, in preparation for a Phase 3b clinical trial aimed at treating amyotrophic lateral sclerosis (ALS). The collaboration involves a Letter of Intent for technology transfer and clinical trial manufacturing at Minaris' facility in Allendale, New Jersey. This partnership aims to enhance BrainStorm's manufacturing capabilities in the U.S. and is part of a broader strategy to support the upcoming clinical trial. Additionally, BrainStorm's collaboration with <a href=\"https://laohu8.com/S/PLUR\">Pluri Inc.</a> in Israel will contribute to the production of clinical trial materials. BrainStorm emphasizes its commitment to advancing the clinical development of NurOwn® through these strategic relationships.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainstorm Cell Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN96421) on May 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nNDLn3CN1:1","article_id":"2538468472","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538468472","pubTimestamp":1748343659,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BrainStorm Cell Therapeutics Inc.  has announced a strategic partnership with Minaris Advanced Therapies for the manufacturing of its experimental therapy, NurOwn, in preparation for a Phase 3b clinical trial aimed at treating amyotrophic lateral sclerosis . The collaboration involves a Letter of Intent for technology transfer and clinical trial manufacturing at Minaris' facility in Allendale, New Jersey. This partnership aims to enhance BrainStorm's manufacturing capabilities in the U.S. and is part of a broader strategy to support the upcoming clinical trial. Additionally, BrainStorm's collaboration with Pluri Inc. in Israel will contribute to the production of clinical trial materials. BrainStorm emphasizes its commitment to advancing the clinical development of NurOwn through these strategic relationships.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-ge","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PLUR":"Pluri Inc.","BCLI":"BrainStorm Cell Therapeutics Inc."},"translate_title":"BrainStorm Cell Therapeutics与Minaris合作推进NurOwn®的3b期ALS临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCLI":0.9,"PLUR":0.9},"content_text":"BrainStorm Cell Therapeutics Partners with Minaris to Advance Phase 3b ALS Clinical Trial for NurOwn®\n    \n\n        BrainStorm Cell Therapeutics Inc. $(BCLI)$ has announced a strategic partnership with Minaris Advanced Therapies for the manufacturing of its experimental therapy, NurOwn®, in preparation for a Phase 3b clinical trial aimed at treating amyotrophic lateral sclerosis (ALS). The collaboration involves a Letter of Intent for technology transfer and clinical trial manufacturing at Minaris' facility in Allendale, New Jersey. This partnership aims to enhance BrainStorm's manufacturing capabilities in the U.S. and is part of a broader strategy to support the upcoming clinical trial. Additionally, BrainStorm's collaboration with Pluri Inc. in Israel will contribute to the production of clinical trial materials. BrainStorm emphasizes its commitment to advancing the clinical development of NurOwn® through these strategic relationships.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainstorm Cell Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN96421) on May 27, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2538468472","isCrawlerRequest":true}